Ion Beam Applications SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Olivier Legrain
- Full Time Employees
- 2,302
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 3, Chemin du Cyclotron Louvain-la-Neuve BU Belgium 1348
- IPO Date
- Jun 13, 1998
- Website
- iba-worldwide.com
- Similar Companies
- Business
- Ion Beam Applications S.A. Ion Beam Applications S.A. designs, produces and markets particle accelerator technologies and equipment primarily for cancer diagnosis and treatment, as well as industrial applications; core offerings span proton therapy systems including the ProteusONE and ProteusPLUS platforms, dosimetry solutions for radiation therapy and medical imaging quality assurance, radiopharma solutions encompassing cyclotrons such as Cyclone Icon and Cyclone Cube, radiosynthesis modules like Synthera, and integrated radiopharmacy facilities, and industrial solutions featuring the Beyond system for sterilization processes. The company operates globally with approximately 2,100 employees across 40 locations in regions including Europe, the United States, Asia-Pacific and emerging markets, targeting hospitals, cancer centers, nuclear medicine departments and industrial sterilizers; headquartered in Louvain-la-Neuve, Belgium, it was founded in 1986 as a spin-off from the University of Louvain's Cyclotron Research Center and holds B Corporation certification for social and environmental performance. Recent developments include the acquisition of PhantomX GmbH in November 2025 to enhance dosimetry with AI-enabled anthropomorphic phantoms for medical imaging quality assurance, the closing of a EUR 135 million refinancing package comprising a EUR 125 million bank club deal and a EUR 10 million subordinated loan to bolster the balance sheet and support growth opportunities, a memorandum of understanding with Varian signed at ASTRO 2025 to advance proton therapy interoperability, strong order intake growth to EUR 195 million as of Q3 2025 driven by radiopharma and four ProteusONE sales, and ongoing progress in carbon therapy partnership ELITRA with installation advancements in APAC.
Company News
Ion Beam Applications SA (IOBCF) Q2 2026 Earnings Call Transcript
BlackRock Inc. Makes New $488.62 Million Investment in Ion Beam Applications SA $IOBCF
Deutsche Bank AG Acquires Shares of 91,839 Ion Beam Applications SA $IOBCF
Ion Beam Applications (OTCMKTS:IOBCF) Trading Up 5.3% – Here’s What Happened
Ion Beam Applications SA (IOBCF) Q4 2025 Earnings Call Transcript
Ion Beam Applications SA (IOBCF) Q3 2025 Earnings Call Transcript
Ion Beam Applications SA (IOBCF) Q4 2024 Earnings Call Transcript
Ion Beam Applications SA (IOBCF) Q2 2024 Earnings Call Transcript
Ion Beam Applications SA (IOBCF) Q4 2023 Earnings Call Transcript
Ion Beam Applications SA (IOBCF) Q4 2022 Earnings Call Transcript
Ion Beam Applications SA (IOBCF) Q2 2022 Earnings Call Transcript